Company - Helogen (Odyssey SpaceWorks)
- Founded
- Country
- 2022
- USA
- Funding
- Yes, ?
- Previous Names
- Odyssey SpaceWorks
- Website
- https://www.helogen.com/
Product/Service
- Classification
- Miscellaneous
- Category
- Microgravity Flight Service (LEO)
In-Space Manufacturing
Microgravity Research Payloads
- Fields
- Automated Microgravity Laboratory
Medicine and Drugs
- Status
- Development, Launched
- First launch
- 2023
First satellite OSW CAZORLA developed in co-operation with EnduroSat launched in November 2023.
High-Throughput Screening & Drug Discovery
Achieve higher fidelity compound screening through the development of more physiologically relevant tissue models. Helogen’s cutting-edge instrumentation, including the Multi-Modal Culture Analyzer, Sequencer, and Bioreactor, lets you accelerate your pipeline by driving new target discovery, leveraging complex disease modeling and expediting compound testing through high-throughput screening. We harness the unique conditions of space to optimize your drug development process, helping you transform breakthroughs into market-ready therapeutics.
Launch Schedule
- HC-252-Conan - Nov 2025 - Drug Development Mission – Radiation mitigation and oncology drug development using Helogen's Multi-Modal Culture Sequencer (MCS).
- HC-263-Cyrus - Mar 2026 - Life Sciences Mission – High-throughput screening drug development, in space manufacturing, and more using Helogen’s MCS and Multi-Modal Culture Analyzer (MCA).
- HC-264-TBD - Jun 2026 - Life Sciences Mission – To be announced soon.
- Helogen's autonomous space laboratories will accelerate the development of bacterial nanocellulose (BNC), unlocking commercial applications on Earth
- Helogen, the space-biology company, today announced a partnership with AgResearch, a New Zealand Crown Research Institute, to develop bacterial nanocellulose (BNC) in space.
- BNC is a breakthrough material with applications that range from advanced wound dressings to flexible sensors.
- For this partnership, the New Zealand scientists will leverage Helogen's autonomous orbital laboratories to produce BNC in conditions that are impossible to replicate on Earth.
- Helogen will hold commercial rights to the materials created as part of the partnership.
- BNC, which represents a USD$250M market, has applications in healthcare, electronics, and advanced materials. Manufacturing BNC in space has the potential to enhance BNC's properties and unlock new market segments.
- Helogen's orbital bio-manufacturing laboratories allow researchers to conduct their experiments without human intervention.
- These laboratories, which are completely autonomous, can complete research projects in as little as three months, as opposed to traditional avenues for space research like the International Space Station that typically take 18-36 months.
Cellular Experiment Laboratory System (CELS)
- The CELS technology is an autonomous biological payload developed by Helogen Corporation to enable sample handling and preparation for in-orbit analysis. CELS focuses on ensuring high-quality biological experimentation comparable with state-of-the-art ground-based research. It is designed for suborbital, hosted orbital, Commercial Low Earth Orbit Destination, and CLPS (Commercial Lunar Payload Services) use.
- NASA TechLeap Prize Announces Ten Winners of Space Technology Payload Challenge, 2025.
- Each winner can receive up to $500,000, plus the opportunity to flight test their technologies.
Status Comment
First CubeSat launched in 2023 but results have not been found.